0000919574-21-001733.txt : 20210216
0000919574-21-001733.hdr.sgml : 20210216
20210216173545
ACCESSION NUMBER: 0000919574-21-001733
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160701
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BRADSHER NEAL C
CENTRAL INDEX KEY: 0001278388
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12830
FILM NUMBER: 21641266
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc.
CENTRAL INDEX KEY: 0000876343
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943127919
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
BUSINESS PHONE: 5105213390
MAIL ADDRESS:
STREET 1: 2173 SALK AVENUE
STREET 2: SUITE 200
CITY: CARLSBAD
STATE: CA
ZIP: 92008
FORMER COMPANY:
FORMER CONFORMED NAME: BIOTIME INC
DATE OF NAME CHANGE: 19930328
4/A
1
ownership.xml
X0306
4/A
2016-07-01
2020-07-02
0
0000876343
Lineage Cell Therapeutics, Inc.
LCTX
0001278388
BRADSHER NEAL C
C/O BROADWOOD CAPITAL INC.
142 WEST 57TH STREET, 11TH FLOOR
NEW YORK
NY
10019
1
0
1
0
OPTION TO PURCHASE COMMON SHARES
1.67
2023-06-30
COMMON SHARES
49440
49440
D
OPTION TO PURCHASE COMMON SHARES
2.55
2022-06-30
COMMON SHARES
24720
24720
D
OPTION TO PURCHASE COMMON SHARES
2.20
2021-06-30
COMMON SHARES
24720
24720
D
This amendment to the Form 4 filed by Neal C. Bradsher on July 2, 2020 (the "July 2020 Form 4") is being made solely to correct the exercise price of certain options to purchase common shares of Lineage Cell Therapeutics, Inc. (the "Issuer") currently held by Mr. Bradsher (collectively, the "Stock Options"). In particular, the respective exercise prices of these reported Stock Options were adjusted following the distribution of shares of common stock of AgeX Therapeutics, Inc. to the Issuer's shareholders on November 28, 2018 (the "AgeX Distribution"). The number of Stock Options was properly adjusted at the time of the AgeX Distribution; however, the exercise prices of these reported Stock Options were not properly adjusted. For the avoidance of doubt, none of the Stock Options reported in this Form 4 amendment or the July 2020 Form 4 filing have been exercised.
These options are currently exercisable.
/s/ Neal C. Bradsher
2021-02-16